Nuvalent Performance dei guadagni passati

Il passato criteri di controllo 0/6

Gli utili di Nuvalent sono diminuiti a un tasso annuo medio di -49.6%, mentre il settore Biotechs ha visto gli utili crescere a un tasso annuo di 19.3%.

Informazioni chiave

-49.6%

Tasso di crescita degli utili

32.4%

Tasso di crescita dell'EPS

Biotechs Crescita del settore	17.0%
Tasso di crescita dei ricavi	n/a
Rendimento del capitale proprio	-20.0%
Margine netto	n/a
Ultimo aggiornamento sui guadagni	30 Sep 2024

Aggiornamenti sulle prestazioni recenti

Nessun aggiornamento

Recent updates

Here's Why We're Not Too Worried About Nuvalent's (NASDAQ:NUVL) Cash Burn Situation

Apr 22

Nuvalent: Pivotal NSCLC Programs Progressing With Additional Data In 2024

Feb 26

Is Nuvalent, Inc. (NASDAQ:NUVL) Trading At A 36% Discount?

Jan 07

Companies Like Nuvalent (NASDAQ:NUVL) Can Afford To Invest In Growth

Sep 23

Here's Why We're Not At All Concerned With Nuvalent's (NASDAQ:NUVL) Cash Burn Situation

Jun 10

We're Interested To See How Nuvalent (NASDAQ:NUVL) Uses Its Cash Hoard To Grow

Feb 24

Here's Why We're Not Too Worried About Nuvalent's (NASDAQ:NUVL) Cash Burn Situation

Sep 13

Nuvalent GAAP EPS of -$0.38 beats by $0.03

Aug 10

Here's Why We're Not At All Concerned With Nuvalent's (NASDAQ:NUVL) Cash Burn Situation

May 28

We're Hopeful That Nuvalent (NASDAQ:NUVL) Will Use Its Cash Wisely

Oct 29

Ripartizione dei ricavi e delle spese

Come Nuvalent guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.

Storia dei guadagni e delle entrate

NasdaqGS:NUVL Ricavi, spese e utili (USD Millions )
Data	Guadagni	Spese G+A	Spese di R&S
30 Sep 24	-224	57	184
30 Jun 24	-174	50	153
31 Mar 24	-146	42	130
31 Dec 23	-126	36	113
30 Sep 23	-114	32	101
30 Jun 23	-100	28	86
31 Mar 23	-89	25	73
31 Dec 22	-82	22	64
30 Sep 22	-73	20	54
30 Jun 22	-66	18	49
31 Mar 22	-57	15	43
31 Dec 21	-46	10	36
30 Sep 21	-36	7	27
30 Jun 21	-28	4	22
31 Mar 21	-27	2	18
31 Dec 20	-15	2	15

Guadagni di qualità: NUVL al momento non è redditizia.

Margine di profitto in crescita: NUVL al momento non è redditizia.

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Andamento degli utili: NUVL non è redditizia e le perdite sono aumentate negli ultimi 5 anni a un tasso pari a 49.6% all'anno.

Accelerare la crescita: Impossibile confrontare la crescita degli utili di NUVL nell'ultimo anno con la sua media quinquennale poiché al momento non è redditizia

Guadagni vs Settore: NUVL non è redditizia, il che rende difficile confrontare la crescita dei suoi utili dell'anno passato con il settore Biotechs ( 16.6% ).

Rendimento del capitale proprio

ROE elevato: NUVL ha un Return on Equity negativo ( -20.01% ), in quanto al momento non è redditizio.

Nuvalent Performance dei guadagni passati

Il passato criteri di controllo 0/6

Informazioni chiave

Aggiornamenti sulle prestazioni recenti

Recent updates

CEO, President & Director exercised options and sold US$1.6m worth of stock

We're Hopeful That Nuvalent (NASDAQ:NUVL) Will Use Its Cash Wisely

Nuvalent Appoints Alice T. Shaw to its Scientific Advisory Board

CFO & Treasurer exercised options and sold US$613k worth of stock

CEO, President & Director notifies of intention to sell stock

CFO & Treasurer notifies of intention to sell stock

Nuvalent: Promising Data Keeps Validating Pipeline And Platform

Nuvalent, Inc. has completed a Follow-on Equity Offering in the amount of $500 million.

Nuvalent: Likely Approvals Coming Up Do Not Justify This Valuation

Nuvalent, Inc. has completed a Follow-on Equity Offering in the amount of $500 million.

Price target increased by 8.1% to US$111

Nuvalent, Inc. has filed a Follow-on Equity Offering in the amount of $350 million.

Nuvalent, Inc. Announces Publication in Cancer Discovery Detailing Design and Characterization of Alk-Selective Inhibitor Nvl-655

CFO & Treasurer exercised options and sold US$564k worth of stock

New major risk - Revenue and earnings growth

Nuvalent (NASDAQ:NUVL) Is In A Strong Position To Grow Its Business

CFO & Treasurer exercised options and sold US$517k worth of stock

Nuvalent, Inc. Announces First Patient Dosed in HEROEX-1 Phase 1a/1b Clinical Trial of NVL-330, its Novel HER2-selective Inhibitor

Nuvalent, Inc. Announces Promotion of Henry Pelish to Chief Scientific Officer

CFO & Treasurer notifies of intention to sell stock

Nuvalent: Making Precise Progress In Its Oncology Pipeline

Independent Director notifies of intention to sell stock

Nuvalent: NVL-655 Could Bring Blockbuster Potential

Chief Legal Officer & Secretary exercised options and sold US$528k worth of stock

Nuvalent, Inc. Receives U.S. FDA Breakthrough Therapy Designation for NVL-655

Nuvalent, Inc., Annual General Meeting, Jun 12, 2024

Here's Why We're Not Too Worried About Nuvalent's (NASDAQ:NUVL) Cash Burn Situation

Price target increased by 10% to US$102

Independent Director notifies of intention to sell stock

Price target increased by 8.6% to US$92.13

Nuvalent: Pivotal NSCLC Programs Progressing With Additional Data In 2024

Price target increased by 7.4% to US$84.83

Nuvalent, Inc. Initiates the Phase 2 Portion of Alkove-1 Clinical Trial for Patients with Alk-Positive Nsclc and Other Solid Tumors

Is Nuvalent, Inc. (NASDAQ:NUVL) Trading At A 36% Discount?

Chief Development Officer notifies of intention to sell stock

Founder notifies of intention to sell stock

Chief Development Officer notifies of intention to sell stock

New minor risk - Share price stability

Price target increased by 11% to US$59.14

Companies Like Nuvalent (NASDAQ:NUVL) Can Afford To Invest In Growth

Nuvalent to Present Preliminary Data from ALKOVE-1 Phase 1/2 Clinical Trial of NVL-655 at 35th AACR-NCI-EORTC Symposium

Nuvalent Initiates the Phase 2 Portion of ARROS-1 Clinical Trial for Patients with Ros1-Positive NSCLC and Other Solid Tumors

New major risk - Revenue and earnings growth

Price target increased by 8.7% to US$50.83

Chief Legal Officer & Secretary notifies of intention to sell stock

Price target increased by 8.7% to US$50.80

Chief Legal Officer & Secretary notifies of intention to sell stock

Chief Development Officer notifies of intention to sell stock

Here's Why We're Not At All Concerned With Nuvalent's (NASDAQ:NUVL) Cash Burn Situation

Chief Development Officer exercised options and sold US$125k worth of stock

Price target increased by 10% to US$46.75

Chief Development Officer exercised options and sold US$113k worth of stock

Chief Development Officer exercised options and sold US$77k worth of stock

Chief Development Officer exercised options and sold US$86k worth of stock

We're Interested To See How Nuvalent (NASDAQ:NUVL) Uses Its Cash Hoard To Grow

Chief Legal Officer & Secretary notifies of intention to sell stock

Chief Development Officer exercised options and sold US$85k worth of stock

Chief Legal Officer & Secretary exercised options and sold US$51k worth of stock

Chief Development Officer exercised options and sold US$121k worth of stock

Nuvalent Inc. Announces Publication in Cancer Discovery Detailing Design and Characterization of ROS1-selective inhibitor NVL-520

Chief Development Officer exercised options and sold US$130k worth of stock

Price target increased to US$43.67

High number of new directors

Chief Legal Officer & Secretary exercised options and sold US$287k worth of stock

Nuvalent, Inc. Reports Preliminary Phase 1 Clinical Data from ARROS-1 Trial that Support Best-In-Class Potential of NVL-520 for Patients withROS1-Positive NSCLC

Chief Development Officer exercised options and sold US$85k worth of stock

Nuvalent, Inc. Currently Enrolling Patients in the Phase 1 Portion of Its Arros-1 Study, A Phase 1/2 Clinical Trial

Chief Development Officer exercised options and sold US$72k worth of stock

Here's Why We're Not Too Worried About Nuvalent's (NASDAQ:NUVL) Cash Burn Situation

Nuvalent, Inc. Present Preliminary Phase 1 Data from ARROS-1 Clinical Trial of NVL-520 at 34th EORTC-NCI-AACR Symposium and Announces Pipeline Updates

Nuvalent GAAP EPS of -$0.38 beats by $0.03

Nuvalent, Inc. Presents New Preclinical Data Supporting Potential Best-In-Class Profile for ALK-Selective Inhibitor NV-655 At IASLC 2022 World Conference on Lung Cancer Annual Meeting

Nuvalent, Inc. Announces Leadership Promotions

Insider exercised options and sold US$278k worth of stock

Nuvalent, Inc.(NasdaqGS:NUVL) dropped from Russell 2000 Growth Index